• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

    11/14/24 5:11:18 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials
    Get the next $MASS alert in real time by email
    SC 13G/A 1 arch-sch13g_18903.htm ARCH VENTURE FUND VII, L.P. - 908 DEVICES INC. -- SCH 13G/A(#4)

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

      (Amendment No. 4)*

     

     

     

     

    908 Devices Inc.

    (Name of Issuer)

       

    Common Stock par value $0.001 per share

     

    (Title of Class of Securities)

      

    65443P102

     

    (CUSIP Number)

      

    September 30, 2024

     

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☒   Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

    CUSIP No.  65443P102

    13G Page 2 of 11 Pages    

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund VII, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    16.4%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

     

    CUSIP No.  65443P102

    13G Page 3 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners VII, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    16.4%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 4 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners VII, LLC

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    16.4%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    OO

     

       

     
     

    CUSIP No.  65443P102

    13G Page 5 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Keith Crandell

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    57,503

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    57,503

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,782,548

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    16.6%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 6 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Clinton Bybee

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    16.4%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 7 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Robert Nelsen

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    16.4%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 8 of 11 Pages    

     

     

    Item 1(a). Name of Issuer

     

    908 Devices Inc. (the “Issuer”).

     

     

    Item 1(b). Address of Issuer's Principal Executive Offices

     

    645 Summer Street, Boston, MA 02210

     

     

    Item 2(a). Name of Person Filing

     

    ARCH Venture Fund VII, L.P. (“ARCH Venture Fund VII”); ARCH Venture Partners VII, L.P. (“AVP VII LP”); ARCH Venture Partners VII, LLC (“AVP VII LLC”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”). The Reporting Entities and the Managing Directors collectively are referred to as the “Reporting Persons”.

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    8755 W. Higgins Road, Suite 1025, Chicago, IL 60631

     

     

    Item 2(c). Citizenship

     

    ARCH Venture Fund VII and AVP VII LP are limited partnerships organized under the laws of the State of Delaware. AVP VII LLC is a limited liability companies organized under the laws of the State of Delaware. Each Managing Director is a US citizen.

     

     

    Item 2(d). Title of Class of Securities

     

    Common stock, par value $0.001 per share.

     

     

    Item 2(e). CUSIP Number

     

    65443P102

     

      

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not Applicable.

     

     
     

    CUSIP No.  65443P102

    13G Page 9 of 11 Pages    

     

    Item 4. Ownership

     

    (a)

    Amount beneficially owned:

     

    ARCH Venture Fund VII is the record owner of 5,725,045 shares of Common Stock (the “Record Shares”) as of September 30, 2024. AVP VII LP, as the sole general partner of ARCH Venture Fund VII, may be deemed to beneficially own the Record Shares. AVP VII LLC, as the sole general partner of AVP VII, may be deemed to beneficially own the Record Shares. As managing directors of AVP VII LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the Record Shares.

     

    In addition, as of September 30, 2024, Crandell is a holder of vested options to purchase 40,910 shares of Common Stock (the “Vested Option Shares”), 13,927 fully vested restricted stock units (“RSUs”), and options to purchase 2,666 shares of Common Stock vesting within sixty days.

     

    (b)

    Percent of class:

     

    See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person (other than Crandell) is based upon 34,822,836 shares of common stock outstanding as of November 7, 2024, as reported on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 12, 2024. For Crandell, the Vested Option Shares were included in the number of shares of Common stock outstanding.

       
    (c) Number of shares as to which such person has:

      (i)

    Sole power to vote or to direct the vote:

     

    See line 5 of the cover sheets.

         
      (ii)

    Shared power to vote or to direct the vote:

     

    See line 6 of the cover sheets.

         
      (iii)

    Sole power to dispose or to direct the disposition:

     

    See line 7 of the cover sheets.

         
      (iv)

    Shared power to dispose or to direct the disposition:

     

    See line 8 of the cover sheets.

         

    Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.

     

    Item 5. Ownership of Five Percent or Less of a Class

    Not Applicable.

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

     

    Not Applicable.

     

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

     

    Item 10. Certification

     

    Not Applicable.

      

     
     

    CUSIP No.  65443P102

    13G Page 10 of 11 Pages    

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:    November 14, 2024

    ARCH VENTURE FUND VII, L.P.

     

    By:       ARCH Venture Partners VII, L.P.

    its General Partner

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                    *               

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, L.P.

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                           *                    

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, LLC

     

    By:                           *                                

    Keith Crandell

    Managing Director

     

     

                                      *                                 

    Keith Crandell

     

     

                                      *                                 

    Robert Nelsen

     

     

                                      *                                 

    Clinton Bybee

     

     

     

     

     

     

     

     

    * By:   /s/ Mark McDonnell                  

    Mark McDonnell as

    Attorney-in-Fact

     

    *         This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney included as Exhibit 2 to the Form 13G relating to the beneficial ownership of shares of 908 Devices Inc. by the Reporting Persons filed with the Securities and Exchange Commission on February 4, 2021, and incorporated herein in its entirety by reference.

     

     
     

    CUSIP No.  65443P102

    13G Page 11 of 11 Pages    

     

     

    Exhibit 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of 908 Devices Inc.

     

    This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

     

     

    Dated:    November 14, 2024

    ARCH VENTURE FUND VII, L.P.

     

    By:       ARCH Venture Partners VII, L.P.

    its General Partner

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                    *              

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, L.P.

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                        *                       

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, LLC

     

    By:                           *                             

    Keith Crandell

    Managing Director

     

     

                                      *                                 

    Keith Crandell

     

     

                                      *                                 

    Robert Nelsen

     

     

                                      *                                 

    Clinton Bybee

     

     

     

     

     

     

     

    * By:   /s/ Mark McDonnell                  

    Mark McDonnell as

    Attorney-in-Fact

     

     

    *         This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney included as Exhibit 2 to the Form 13G relating to the beneficial ownership of shares of 908 Devices Inc. by the Reporting Persons filed with the Securities and Exchange Commission on February 4, 2021, and incorporated herein in its entirety by reference.

     

     
    Get the next $MASS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASS

    DatePrice TargetRatingAnalyst
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    2/7/2023$14.00Overweight
    Stephens
    3/8/2022$40.00 → $30.00Outperform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $MASS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Knopp Kevin J. bought $64,200 worth of shares (10,000 units at $6.42), increasing direct ownership by 2% to 508,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/13/24 4:42:46 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $57,700 worth of shares (10,000 units at $5.77), increasing direct ownership by 2% to 498,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/10/24 6:36:05 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $58,300 worth of shares (10,000 units at $5.83), increasing direct ownership by 2% to 488,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/9/24 4:34:35 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 5:11:18 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 4:25:10 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      7/8/24 4:32:41 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Financials

    Live finance-specific insights

    See more
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results

      Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to

      3/4/25 7:45:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

      WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

      3/4/25 7:30:00 AM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MASS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by 908 Devices Inc.

      DEFA14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:03:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form DEF 14A filed by 908 Devices Inc.

      DEF 14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:00:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form SCHEDULE 13G filed by 908 Devices Inc.

      SCHEDULE 13G - 908 Devices Inc. (0001555279) (Subject)

      4/7/25 4:18:42 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

      6/25/24 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

      908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as

      3/2/22 4:30:00 PM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel

      Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod

      8/2/21 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 908 Devices downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      11/13/24 8:05:47 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Stephens initiated coverage on 908 Devices with a new price target

      Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00

      2/7/23 6:37:28 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SVB Leerink reiterated coverage on 908 Devices with a new price target

      SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously

      3/8/22 4:31:59 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Awm Investment Company, Inc. claimed ownership of 5,199,924 shares (SEC Form 3)

      3 - 908 Devices Inc. (0001555279) (Issuer)

      3/14/25 4:27:06 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by President and CEO Knopp Kevin J.

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:30 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Chief Financial Officer Griffith Joseph H. Iv

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:08 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 908 Devices Equips rescEU Disaster Preparedness Reserve with Advanced Chemical Detection

      The company's handheld devices are incorporated in strategic CBRN stockpiles 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that its devices for rapid chemical detection at the point of need are being included in strategic stockpiles within Europe as part of rescEU, an EU-funded project that is establishing a reserve of disaster response capabilities. These reserves include stockpiles of chemical, biological, radiation and nuclear (CBRN) capabilities for detection, sampling, identification and monitoring due to unintentional disasters or intentional attacks. Over the past six months, the Company has shipped 108 devices to Europ

      4/30/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation

      Multiple handheld MX908 devices will be deployed to detect, identify and mitigate illicit drugs like fentanyl, protecting communities amid the opioid crisis 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program. The MX908 provides first responders with fast, actionable information when dea

      4/22/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials